Is Breast Surgery Necessary for Breast Carcinoma in Complete Remission Following Neoadjuvant Chemotherapy?

Is Breast Surgery Necessary for Breast Carcinoma in Complete Remission Following Neoadjuvant Chemotherapy? Geburtshilfe Frauenheilkd. 2018 Jan;78(1):48-53 Authors: Richter H, Hennigs A, Schaefgen B, Hahn M, Blohmer JU, Kümmel S, Kühn T, Thill M, Friedrichs K, Sohn C, Golatta M, Heil J Abstract The likelihood of pathological complete remission (pCR) of breast cancer following neoadjuvant chemotherapy (NACT) is increasing; most of all in the triple negative and HER2 positive tumour subgroups. The question thus arises whether or not breast surgery is necessary when there is complete remission after NACT, and whether it provides any improvement of the oncological treatment result when tumour is no longer detectable. Avoiding surgery and possibly even radiotherapy would only be conceivable on the basis of a reliable diagnosis of pCR without operating. Current imaging does not achieve the necessary sensitivity and specificity to assure the diagnosis of pathological complete remission. Further studies are therefore required to determine which methods are best able to evaluate tumour response to NACT. Studies on image-guided, minimally invasive biopsies after NACT have delivered first promising results towards diagnosing pCR before surgery and could provide the basis for further studies on the possibility of avoiding surgery in this specific patient collective. PMID: 29375145 [PubMed - in process]
Source: Geburtshilfe und Frauenheilkunde - Category: OBGYN Tags: Geburtshilfe Frauenheilkd Source Type: research

Related Links:

Conditions:   HER2-positive Breast Cancer;   Breast Cancer;   Breast Cancer Stage;   Recurrent Breast Cancer;   Metastatic Breast Cancer;   HER2 Positive Breast Carcinoma Interventions:   Drug: Palbociclib;   Drug: T-DM1 Sponsors:   University of Arizona;   Pfizer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 12 May 2018 Source:Genes & Diseases Author(s): Yixiao Feng, Mia Spezia, Shifeng Huang, Chengfu Yuan, Zongyue Zeng, Linghuan Zhang, Xiaojuan Ji, Wei Liu, Bo Huang, Wenping Luo, Bo Liu, Yan Lei, Scott Du, Akhila Vuppalapati, Hue H. Luu, Rex C. Haydon, Tong-Chuan He, Guosheng Ren As the most commonly occurring cancer in women worldwide, breast cancer poses a formidable public health challenge on a global scale. Breast cancer consists of a group of biologically and molecularly heterogeneous diseases originated from the breast. While the risk factors associated with this cancer varies wit...
Source: Genes and Diseases - Category: Genetics & Stem Cells Source Type: research
Molecules, Vol. 23, Pages 1160: (−)-Epigallocatechin 3-Gallate Synthetic Analogues Inhibit Fatty Acid Synthase and Show Anticancer Activity in Triple Negative Breast Cancer Molecules doi: 10.3390/molecules23051160 Authors: Joan Crous-Masó Sònia Palomeras Joana Relat Cristina Camó Úrsula Martínez-Garza Marta Planas Lidia Feliu Teresa Puig (−)-Epigallocatechin 3-gallate (EGCG) is a natural polyphenol from green tea with reported anticancer activity and capacity to inhibit the lipogenic enzyme fatty acid synthase (FASN), which is overexpressed in several hum...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
Authors: Chiorean AR, Szep MB, Feier DS, Duma M, Chiorean MA, Strilciuc Ș Abstract AIMS: The purpose of this study was to determine the impact of strain elastography (SE) on the Breast Imaging Reporting Data System (BI-RADS) classification depending on invasive lobular carcinoma (ILC) lesion size. MATERIALS AND METHODS: We performed a retrospective analysis on a sample of 152 female subjects examined between January 2010 - January 2017. SE was performed on all patients and ILC was subsequently diagnosed by surgical or ultrasound-guided biopsy. BI-RADS 1, 2, 6 and Tsukuba BGR cases were omitted. BI-RADS scores ...
Source: Medical Ultrasonography - Category: Radiology Tags: Med Ultrason Source Type: research
CONCLUSION: PLAC-B as neoadjuvant treatment of this subpopulation with TNBC and ER/PR+ patients is effective and safe. Further studies are necessitated. PMID: 29744672 [PubMed - as supplied by publisher]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Clin Drug Investig Source Type: research
ConclusionPLAC-B as neoadjuvant treatment of this subpopulation with TNBC and ER/PR+ patients is effective and safe. Further studies are necessitated.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
Authors: Ahmed ST, Ahmed AM, Musa DH, Sulayvani FK, Al-Khyatt M, Pity IS Abstract Background and objectives: To date, many tumor markers have been used to predict prognosis and therapeutic response in patients with breast cancer. The well established and routinely applied tumor markers are the estrogen-receptor, progesterone-receptor and Her2/neu-receptor. In the current study, we aimed to highlight any association of the proliferation index (Ki67) in breast infiltrative duct carcinoma with the tumor grade, tumor size and nodal status in addition to hormone receptor status. Tissue sections were stained immunohistoc...
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
CONCLUSIONS High HDAC3 expression is closely correlated with ER-negative expression, PR-negative expression, HER2 overexpression, PT stage, and clinical stage of breast tumors. HDAC3 may be an appropriate prognostic indicator in patients with invasive ductal breast cancer. PMID: 29680858 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
CONCLUSIONS: With this unbiased study design and representative group of DCIS patients treated by BCS alone, COX-2, HER2, and periductal fibrosis were revealed as promising markers predicting progression of DCIS into iIBC. Validation will be done in independent data sets. Ultimately, this will aid individual risk stratification of women with primary DCIS. PMID: 29685879 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Conditions:   Breast Neoplasms;   Breast Diseases;   Capecitabine;   HER2-positive Breast Cancer;   HER2 Positive Breast Carcinoma Interventions:   Drug: RC48-ADC;   Drug: Lapatinib;   Drug: Capecitabine Sponsor:   RemeGen Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Breast Carcinoma | Breast Surgery | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | HER2 | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Study